Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCX NASDAQ:HSAQ NYSE:INFU NYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.84+0.4%$3.03$0.17▼$1.27$59.37M0.514.65 million shs18,359 shsHSAQHealth Sciences Acquisitions Co. 2$2.68+9.8%$3.05$9.41▼$13.80$30.05M0.09205,918 shs580,304 shsINFUInfuSystem$6.07+3.8%$5.97$4.61▼$9.97$127.57M1.81151,744 shs287,464 shsNSPRInspireMD$2.45-8.2%$2.42$1.99▼$3.80$75.06M0.6104,128 shs140,277 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell+0.35%-27.37%+16.39%+1,729.90%+153.57%HSAQHealth Sciences Acquisitions Co. 2+9.84%-21.18%-7.27%+10.74%-57.32%INFUInfuSystem+3.76%+3.58%-1.46%+27.79%-12.03%NSPRInspireMD-8.24%+0.41%+8.65%-4.07%-17.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/AINFUInfuSystem2.864 of 5 stars2.03.00.00.02.54.21.9NSPRInspireMD3.6392 of 5 stars3.53.00.00.03.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2 0.00N/AN/AN/AINFUInfuSystem 4.00Strong Buy$12.50105.93% UpsideNSPRInspireMD 3.00Buy$4.5083.67% UpsideCurrent Analyst Ratings BreakdownLatest HSAQ, INFU, CTCX, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,807.92N/AN/A$1.07 per share2.65HSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/AINFUInfuSystem$137.58M0.93$0.47 per share12.79$2.47 per share2.46NSPRInspireMD$7.03M10.68N/AN/A$1.83 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/AINFUInfuSystem$870K$0.14101.1819.58N/A1.12%2.78%1.41%N/ANSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HSAQHealth Sciences Acquisitions Co. 2N/A0.170.61INFUInfuSystem0.501.981.59NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HSAQHealth Sciences Acquisitions Co. 289.71%INFUInfuSystem71.13%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HSAQHealth Sciences Acquisitions Co. 221.90%INFUInfuSystem11.40%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableINFUInfuSystem41021.02 million19.10 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableHSAQ, INFU, CTCX, and NSPR HeadlinesRecent News About These CompaniesInspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript3 hours ago | seekingalpha.comInspireMD Reports Second Quarter 2025 Financial ResultsAugust 5 at 8:00 AM | globenewswire.comInspireMD Q2 2025 Earnings PreviewAugust 4 at 12:55 AM | msn.comWhat to Expect from InspireMD Inc (NSPR) Q2 2025 EarningsAugust 4 at 12:55 AM | finance.yahoo.comInvestors in InspireMD (NASDAQ:NSPR) from five years ago are still down 60%, even after 11% gain this past weekAugust 3 at 8:07 PM | finance.yahoo.comInspireMD, Inc. (NYSE:NSPR) CEO Marvin Slosman Acquires 10,330 SharesAugust 2, 2025 | marketbeat.comInspireMD, Inc. (NYSE:NSPR) Director Paul Stuka Acquires 20,661 SharesAugust 2, 2025 | marketbeat.comThomas J. Kester Acquires 30,991 Shares of InspireMD, Inc. (NYSE:NSPR) StockAugust 2, 2025 | marketbeat.comInspireMD, Inc. (NYSE:NSPR) Director Acquires $99,999.24 in StockAugust 2, 2025 | marketbeat.comMarvin Slosman Acquires 10,330 Shares of InspireMD, Inc. (NYSE:NSPR) StockAugust 2, 2025 | insidertrades.comInspireMD brings in $58M, adds former Axonics CEO to boardJuly 31, 2025 | massdevice.comInspireMD Announces the Appointment of Raymond W. Cohen to its Board of DirectorsJuly 31, 2025 | globenewswire.comInspireMD Announces Combined Financings of $58 MillionJuly 31, 2025 | globenewswire.comHead-To-Head Contrast: InspireMD (NYSE:NSPR) and Nemaura Medical (NASDAQ:NMRD)July 29, 2025 | americanbankingnews.comInspireMD to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | globenewswire.comInspireMD Launches CGuard Prime Carotid Stent System in the U.S.July 11, 2025 | zacks.comInspireMD’s CGuard Prime Carotid Stent System Launched in United StatesJuly 10, 2025 | evtoday.comEInspireMD stock rises after US commercial launch of carotid stent systemJuly 10, 2025 | au.investing.comInspireMD launches carotid stent in U.S. after FDA approvalJuly 10, 2025 | massdevice.comInspireMD Shares Rise on U.S. Rollout of CGuard Prime Carotid StentJuly 10, 2025 | msn.comInspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of StrokeJuly 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSAQ, INFU, CTCX, and NSPR Company DescriptionsCarmell NASDAQ:CTCX$2.84 +0.01 (+0.35%) As of 08/4/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ$2.68 +0.24 (+9.84%) As of 08/4/2025Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.InfuSystem NYSE:INFU$6.07 +0.22 (+3.76%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$6.15 +0.08 (+1.32%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.InspireMD NYSE:NSPR$2.45 -0.22 (-8.24%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$2.30 -0.15 (-6.12%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Soars After Blowout Earnings Report Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? Applied Digital: Why a Surge in Bullish Bets Signals a New Era META Gets Huge Upgrades: How High Analysts Think Shares Could Go Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
